CKD and cardiovascular components of the primary endpoint contributed to the risk reduction. In the trial, semaglutide 1.0 mg appeared to have a safe and well-tolerated profile in line with previous semaglutide 1.0 mg trials. Novo Nordisk expects to file for regulatory approvals of a label expansion for Ozempic in the U.S. and EU in 2024. Once-weekly subcutaneous semaglutide is approved in 0.5 mg, 1.0 mg, and 2.0 mg doses under the brand name Ozempic and indicated as an adjunct to diet and exercise for type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Read Next: Novo Nordisk's Weight Loss Drugs Ozempic, Wegovy Show Promise For Diabetic Patients Undergoing Hip Replacement. Price Action: NVO shares are down 1.79% at $125.66 during the premarket session on the last check Tuesday.